Evaluation of the Effects of Laughter Yoga

NCT07524231 | Recruiting

• 1 other identifier: 2024/15-01
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

This randomized controlled study aims to evaluate the effects of laughter yoga on pain intensity, fatigue, and beta-endorphin levels in patients with Multiple Sclerosis. Laughter yoga, a complementary therapy combining breathing exercises and laughter techniques, may help improve symptom management and psychological well-being in individuals with MS.

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis; pain; Laughter Yoga,; fatigue

Outcome Measures

Primary Outcomes (1)

• Change in pain intensity measured by Visual Analog Scale (VAS) at [time point]

  Pain intensity will be assessed using the Visual Analog Scale (VAS), a 10 cm scale ranging from 0 (no pain) to 10 (worst imaginable pain). Participants will indicate their pain level by marking on the scale, and the score will be determined by measuring the distance in centimeters or millimeters.

  Baseline and week 4

Secondary Outcomes (2)

• Fatigue Level

  1 month

• Change in plasma beta-endorphin levels measured by ELISA at baseline and week 4

  Baseline and week 4

Study Arms (2)

Experimental Group

EXPERIMENTAL

Patients with Multiple Sclerosis who will receive laughter yoga in addition to routine care.

Behavioral: Laughter Yoga

Control Group

NO INTERVENTION

Patients with Multiple Sclerosis who will receive routine care without laughter yoga.

Interventions

Laughter Yoga BEHAVIORAL

A complementary intervention including breathing exercises, stretching, relaxation techniques, and laughter exercises applied to patients with Multiple Sclerosis.

Experimental Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Being over 18 years old
• Being able to communicate adequately
• Volunteering to participate in the research

You may not qualify if:

• Unwillingness to participate in the study
• Having severe cognitive impairment that prevents understanding or participation in the intervention
• Having a psychiatric disorder that may affect participation in the study
• Experiencing an acute MS relapse during the study period
• Having another serious neurological or chronic disease that may affect the study outcomes
• Regular participation in another complementary therapy program similar to laughter yoga
• Communication problems that prevent participation in the intervention sessions

Sponsors & Collaborators

• Firat University: lead

Study Sites (1)

Gül DURAL

Elâzığ, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis; Pain; Fatigue

Interventions

Laughter Therapy

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Mind-Body Therapies; Complementary Therapies; Therapeutics

Central Study Contacts

Gül DURAL, pHD

CONTACT

04242370000; gulkaya@firat.edu.tr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor

Study Record Dates

• First Submitted: March 11, 2026
• First Posted: April 13, 2026
• Study Start: March 10, 2026
• Primary Completion (Estimated): July 10, 2026
• Study Completion (Estimated): August 10, 2026
• Last Updated: April 13, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)